EMG
VKTX icon

Ellington Management Group’s Viking Therapeutics VKTX Stock Holding History

Ellington Management Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-36,600
Closed -$171K – 431
2020
Q1 		$171K Buy
+36,600
New +$225K 0.04% 452
2019
Q4 		– Sell
-22,700
Closed -$156K – 768
2019
Q3 		$156K Buy
+22,700
New +$169K 0.03% 528
2019
Q2 		– Sell
-18,500
Closed -$184K – 794
2019
Q1 		$184K Buy
+18,500
New +$155K 0.03% 484

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Ellington Management Group's VKTX Position: Q2 2020 in Review

Ellington Management Group sold out of Viking Therapeutics (VKTX) in Q2 2020, closing a stake of 36,600 shares — an estimated $171K sold.

Ellington Management Group first reported a position in VKTX in Q1 2019 and held it in 3 quarters. The position peaked at $184K in Q1 2019. 138 funds tracked by Wall St. Rank hold VKTX as of Q2 2020.

  • Ellington Management Group reported no remaining Viking Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Ellington Management Group sold 36,600 Viking Therapeutics shares in Q2 2020, an estimated $171K.
  • Ellington Management Group first reported a position in Viking Therapeutics in Q1 2019 and held it in 3 quarters.
  • Ellington Management Group's Viking Therapeutics position peaked at $184K in Q1 2019.
  • 138 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2020.

Based on Ellington Management Group's 13F filing for Q2 2020, filed 17 Aug 2020.